Kestra Medical Technologies, Ltd. (KMTS)
NASDAQ: KMTS · Real-Time Price · USD
22.98
+0.66 (2.96%)
At close: Jan 15, 2026, 4:00 PM EST
22.98
0.00 (0.00%)
Pre-market: Jan 16, 2026, 4:28 AM EST
KMTS Stock Forecast
Stock Price Forecast
The 6 analysts that cover KMTS stock have a consensus rating of "Buy" and an average price target of $28.67, which forecasts a 24.76% increase in the stock price over the next year. The lowest target is $25 and the highest is $32.
Price Target: $28.67 (+24.76%)
Analyst Consensus: Buy
* Price targets were last updated on Dec 15, 2025.
Analyst Ratings
The average analyst rating for KMTS stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $22 → $25 | Hold | Maintains | $22 → $25 | +8.79% | Dec 15, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $27 → $28 | Buy | Maintains | $27 → $28 | +21.85% | Dec 12, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $27 → $30 | Buy | Maintains | $27 → $30 | +30.55% | Dec 12, 2025 |
| BTIG | BTIG | Strong Buy Initiates $32 | Strong Buy | Initiates | $32 | +39.25% | Nov 18, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $28 → $27 | Buy | Maintains | $28 → $27 | +17.49% | Jul 17, 2025 |
Financial Forecast
Revenue This Year
92.88M
from 59.82M
Increased by 55.27%
Revenue Next Year
92.77M
from 92.88M
Decreased by -0.12%
EPS This Year
-2.36
from -5.13
EPS Next Year
-2.35
from -2.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2026 | 2027 | 2027 | 2028 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|
| High | 96.1M | 96.1M | |||||
| Avg | 92.9M | 92.8M | |||||
| Low | 89.0M | 88.5M |
Revenue Growth
| Revenue Growth | 2026 | 2026 | 2027 | 2027 | 2028 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|
| High | 60.6% | 3.4% | |||||
| Avg | 55.3% | -0.1% | |||||
| Low | 48.7% | -4.7% |
EPS Forecast
| EPS | 2026 | 2026 | 2027 | 2027 | 2028 | 2028 |
|---|---|---|---|---|---|---|
| High | -2.43 | -2.34 | ||||
| Avg | -2.36 | -2.35 | ||||
| Low | -2.27 | -2.32 |
EPS Growth
| EPS Growth | 2026 | 2026 | 2027 | 2027 | 2028 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.